Expanded indication for GSK's Boostrix approved

GlaxoSmithKline received approval from the FDA to market Boostrix for adults. The vaccine, which is designed to protect against tetanus, diphtheria and pertussis (whooping cough), was previously approved for ages 10-18. GSK now has the green light to use the booster in adults ages 19-64 as well. Boostrix will join a line of GSK vaccines for adults which also include vaccines against hepatitis A and B and the flu. Release

Suggested Articles

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts secure supplies if any immunizations prove effective.

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.